Iproplatin and carboplatin induced toxicities: Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG)

M. Van Glabbeke, J. Renard, H. M. Pinedo, F. Cavalli, J. Vermorken, C. Sessa, R. Abele, M. Clavel, S. Monfardini

Research output: Contribution to journalArticle

Abstract

Data of five phase II clinical trials on iproplatin and carboplatin, conducted by the ECTG, have been pooled in order to evaluate the extent of toxicities of these compounds. One hundred and seventy patients treated with iproplatin and 65 patients treated with carboplatin were evaluable. Most of them (81%) had been previously treated with chemotherapy. Doses ranged from 180 to 300 mg/m2 every 4 weeks for iproplatin, and from 350 to 450 mg/m2 every 5 weeks for carboplatin, according to the initial status of the patient. WHO criteria were used to grade toxic effects. Weekly blood counts were performed, and lowest observed counts were analysed by non-parametric methods. Censored data were analysed by actuarial methods. Thrombocytopenia was the dose-limiting toxicity and was dose related. Leucopenia was less severe. The risk of thrombocytopenia varied largely amongst patients, and could be predicted from the initial platelet count, the initial creatinine level and prior therapy with alkylating agents. The cumulative risk increased with the total dose, but with a decreasing hazard rate, and without additional delay to platelet recovery. Nausea, vomiting and diarrhoea were the most frequently observed non-haematological side-effects, and were more severe with iproplatin than with carboplatin. Peripheral neuropathy was observed in some cases, but could be due to prior treatments. Renal toxicity did not cause major problems. Our results confirm the findings of the phase 1 trials: thrombocytopenia is dose-limiting for both drugs, and renal side-effects are negligible. The risk model of thrombocytopenia, consistent with Egorin's model for carboplatin, could serve as a basis for dose adjustment. The feasibility of the scheme could be insufficient for prolonged treatment.

Original languageEnglish
Pages (from-to)255-262
Number of pages8
JournalEuropean Journal of Cancer and Clinical Oncology
Volume24
Issue number2
DOIs
Publication statusPublished - 1988

Fingerprint

Phase II Clinical Trials
Carboplatin
Clinical Trials
Thrombocytopenia
Kidney
Poisons
Alkylating Agents
Leukopenia
Peripheral Nervous System Diseases
Drug-Related Side Effects and Adverse Reactions
Platelet Count
Nausea
Vomiting
Diarrhea
Creatinine
Therapeutics
Blood Platelets
iproplatin
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Iproplatin and carboplatin induced toxicities : Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG). / Van Glabbeke, M.; Renard, J.; Pinedo, H. M.; Cavalli, F.; Vermorken, J.; Sessa, C.; Abele, R.; Clavel, M.; Monfardini, S.

In: European Journal of Cancer and Clinical Oncology, Vol. 24, No. 2, 1988, p. 255-262.

Research output: Contribution to journalArticle

Van Glabbeke, M. ; Renard, J. ; Pinedo, H. M. ; Cavalli, F. ; Vermorken, J. ; Sessa, C. ; Abele, R. ; Clavel, M. ; Monfardini, S. / Iproplatin and carboplatin induced toxicities : Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG). In: European Journal of Cancer and Clinical Oncology. 1988 ; Vol. 24, No. 2. pp. 255-262.
@article{ad84e78289ed4650a6fddcdb079f282f,
title = "Iproplatin and carboplatin induced toxicities: Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG)",
abstract = "Data of five phase II clinical trials on iproplatin and carboplatin, conducted by the ECTG, have been pooled in order to evaluate the extent of toxicities of these compounds. One hundred and seventy patients treated with iproplatin and 65 patients treated with carboplatin were evaluable. Most of them (81{\%}) had been previously treated with chemotherapy. Doses ranged from 180 to 300 mg/m2 every 4 weeks for iproplatin, and from 350 to 450 mg/m2 every 5 weeks for carboplatin, according to the initial status of the patient. WHO criteria were used to grade toxic effects. Weekly blood counts were performed, and lowest observed counts were analysed by non-parametric methods. Censored data were analysed by actuarial methods. Thrombocytopenia was the dose-limiting toxicity and was dose related. Leucopenia was less severe. The risk of thrombocytopenia varied largely amongst patients, and could be predicted from the initial platelet count, the initial creatinine level and prior therapy with alkylating agents. The cumulative risk increased with the total dose, but with a decreasing hazard rate, and without additional delay to platelet recovery. Nausea, vomiting and diarrhoea were the most frequently observed non-haematological side-effects, and were more severe with iproplatin than with carboplatin. Peripheral neuropathy was observed in some cases, but could be due to prior treatments. Renal toxicity did not cause major problems. Our results confirm the findings of the phase 1 trials: thrombocytopenia is dose-limiting for both drugs, and renal side-effects are negligible. The risk model of thrombocytopenia, consistent with Egorin's model for carboplatin, could serve as a basis for dose adjustment. The feasibility of the scheme could be insufficient for prolonged treatment.",
author = "{Van Glabbeke}, M. and J. Renard and Pinedo, {H. M.} and F. Cavalli and J. Vermorken and C. Sessa and R. Abele and M. Clavel and S. Monfardini",
year = "1988",
doi = "10.1016/0277-5379(88)90262-3",
language = "English",
volume = "24",
pages = "255--262",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "2",

}

TY - JOUR

T1 - Iproplatin and carboplatin induced toxicities

T2 - Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG)

AU - Van Glabbeke, M.

AU - Renard, J.

AU - Pinedo, H. M.

AU - Cavalli, F.

AU - Vermorken, J.

AU - Sessa, C.

AU - Abele, R.

AU - Clavel, M.

AU - Monfardini, S.

PY - 1988

Y1 - 1988

N2 - Data of five phase II clinical trials on iproplatin and carboplatin, conducted by the ECTG, have been pooled in order to evaluate the extent of toxicities of these compounds. One hundred and seventy patients treated with iproplatin and 65 patients treated with carboplatin were evaluable. Most of them (81%) had been previously treated with chemotherapy. Doses ranged from 180 to 300 mg/m2 every 4 weeks for iproplatin, and from 350 to 450 mg/m2 every 5 weeks for carboplatin, according to the initial status of the patient. WHO criteria were used to grade toxic effects. Weekly blood counts were performed, and lowest observed counts were analysed by non-parametric methods. Censored data were analysed by actuarial methods. Thrombocytopenia was the dose-limiting toxicity and was dose related. Leucopenia was less severe. The risk of thrombocytopenia varied largely amongst patients, and could be predicted from the initial platelet count, the initial creatinine level and prior therapy with alkylating agents. The cumulative risk increased with the total dose, but with a decreasing hazard rate, and without additional delay to platelet recovery. Nausea, vomiting and diarrhoea were the most frequently observed non-haematological side-effects, and were more severe with iproplatin than with carboplatin. Peripheral neuropathy was observed in some cases, but could be due to prior treatments. Renal toxicity did not cause major problems. Our results confirm the findings of the phase 1 trials: thrombocytopenia is dose-limiting for both drugs, and renal side-effects are negligible. The risk model of thrombocytopenia, consistent with Egorin's model for carboplatin, could serve as a basis for dose adjustment. The feasibility of the scheme could be insufficient for prolonged treatment.

AB - Data of five phase II clinical trials on iproplatin and carboplatin, conducted by the ECTG, have been pooled in order to evaluate the extent of toxicities of these compounds. One hundred and seventy patients treated with iproplatin and 65 patients treated with carboplatin were evaluable. Most of them (81%) had been previously treated with chemotherapy. Doses ranged from 180 to 300 mg/m2 every 4 weeks for iproplatin, and from 350 to 450 mg/m2 every 5 weeks for carboplatin, according to the initial status of the patient. WHO criteria were used to grade toxic effects. Weekly blood counts were performed, and lowest observed counts were analysed by non-parametric methods. Censored data were analysed by actuarial methods. Thrombocytopenia was the dose-limiting toxicity and was dose related. Leucopenia was less severe. The risk of thrombocytopenia varied largely amongst patients, and could be predicted from the initial platelet count, the initial creatinine level and prior therapy with alkylating agents. The cumulative risk increased with the total dose, but with a decreasing hazard rate, and without additional delay to platelet recovery. Nausea, vomiting and diarrhoea were the most frequently observed non-haematological side-effects, and were more severe with iproplatin than with carboplatin. Peripheral neuropathy was observed in some cases, but could be due to prior treatments. Renal toxicity did not cause major problems. Our results confirm the findings of the phase 1 trials: thrombocytopenia is dose-limiting for both drugs, and renal side-effects are negligible. The risk model of thrombocytopenia, consistent with Egorin's model for carboplatin, could serve as a basis for dose adjustment. The feasibility of the scheme could be insufficient for prolonged treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023876386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023876386&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(88)90262-3

DO - 10.1016/0277-5379(88)90262-3

M3 - Article

C2 - 3281842

AN - SCOPUS:0023876386

VL - 24

SP - 255

EP - 262

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 2

ER -